The new research platform, being developed by Merck and Accenture, will enable an ecosystem that accelerates innovation by creating open, industry-standard application programming interfaces for core research functions, allowing researchers to rapidly adopt new capabilities.
Scientific application providers, content providers and technology innovators will benefit from lower barriers to entry as they bring new capabilities to market, helping life sciences companies re-imagine processes, user experiences, and approaches to data-intensive research.
The platform will allow life sciences researchers and informatics professionals to quickly aggregate, access and analyse research data from multiple applications.
According to the companies, data will now be accessible through a single set of interfaces, with integrated workflow, reporting and analytics capabilities.
Incorporating a modern user interface and a secure, multi-tenant environment, the platform will unify user experience elements and enable easier collaboration across the research and development enterprise, including with external partners.
Merck is collaborating with Accenture on this launch and will be the first pharmaceutical company to use the platform.
The platform is built on AWS, leveraging its secure cloud services to help increase operational efficiency, strengthen business intelligence, and quickly develop innovative products and services.
Accenture is also forming a coalition of clients to govern and further advance the capabilities of this platform, offering an opportunity for pre-competitive industry collaboration.
The platform is available to pharmaceutical, biotech and scientific research organisations that are seeking unique approaches to solve research informatics challenges.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval